Anti-factor XIII A subunit (FXIII-A) autoantibodies block FXIII-A2B2 assembly and steal FXIII-A from native FXIII-A2B2

Journal of Thrombosis and Haemostasis

Volumn 13, Issue 5, 2015, Pages 802-814

  Souri, M ^a,b   Osaki, T ^a,b   Ichinose, A ^a,b  

^a YAMAGATA UNIVERSITY   (Japan)

^b The Japanese Collaborative Research Group (JCRG) Acquired hemorrha philia due to anti factor XIII autoantibodies (AH13)   (Japan)

Author keywords

Antibody diversity; Autoimmune diseases; Chronic disease; Hemorrhagic disorders; Immunosuppressive agents

Indexed keywords

AUTOANTIBODY; BLOOD CLOTTING FACTOR 13 A2B2; BLOOD CLOTTING FACTOR 13A; BLOOD CLOTTING FACTOR 13B; CALCIUM; FACTOR XIII A AUTOANTIBODY; FACTOR XIII AA AUTOANTIBODY; FACTOR XIII AB AUTOANTIBODY; FACTOR XIII B AUTOANTIBODY; FIBRIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G4; NEUTRALIZING ANTIBODY; THROMBIN; UNCLASSIFIED DRUG; BLOOD CLOTTING FACTOR 13; ISOENZYME; SERINE PROTEINASE INHIBITOR;

ADULT; ANTIBODY DETECTION; ANTIBODY SCREENING; ANTIBODY SPECIFICITY; ANTICOAGULATION; ARTICLE; AUTOIMMUNE BLOOD CLOTTING FACTOR 13 DEFICIENCY; AUTOIMMUNE DISEASE; BLOOD CLOTTING; BLOOD CLOTTING FACTOR 13 DEFICIENCY; CLINICAL ARTICLE; COMPLEX FORMATION; DIMERIZATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOPRECIPITATION; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN CLEAVAGE; PROTEIN CROSS LINKING; CHEMISTRY; IMMUNOLOGY;

AUTOANTIBODIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FACTOR XIII; HUMANS; ISOENZYMES; SERINE PROTEINASE INHIBITORS;

EID: 84928769131     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12877     Document Type: Article

References (40)

1. Ichinose A. Physiopathology and regulation of factor XIII. Thromb Haemost 2001; 86: 57-65.
2. Nugent DJ. Prophylaxis in rare coagulation disorders - factor XIII deficiency. Thromb Res 2006; 118(Suppl. 1): S23-8.
3. Biswas A, Ivaskevicius V, Thomas A, Oldenburg J. Coagulation factor XIII deficiency. Diagnosis, prevalence and management of inherited and acquired forms. Hamostaseologie 2014; 34: 160-6.
4. Muszbek L, Ariëns RA, Ichinose A; ISTH SSC Subcommittee on Factor XIII. Factor XIII: recommended terms and abbreviations. J Thromb Haemost 2007; 5: 181-3.
5. Kohler HP, Ichinose A, Seitz R, Ariens RA, Muszbek L; Factor XIII and Fibrinogen SSC Subcommittee of the ISTH. Diagnosis and classification of factor XIII deficiencies. J Thromb Haemost 2011; 9: 1404-6.
6. Lorand L. Acquired inhibitors of fibrin stabilization: a class of hemorrhagic disorders of diverse origins. In: Green D, ed. Anticoagulants, Physiologic, Pathologic and Pharmacologic. Boca Raton, FL: CRC Press, 1994:169-91.
7. Ichinose A, Izumi T, Hashiguchi T. The normal and abnormal genes of the a and b subunits in coagulation factor XIII. Semin Thromb Hemost 1996; 22: 385-91.
8. Ichinose A. Hemorrhagic acquired factor XIII deficiency and acquired hemorrhaphilia 13 revisited. Semin Thromb Hemost 2011; 37: 382-8.
9. Ichinose A, Souri M; Japanese collaborative research group on 'Acquired haemorrha-philia due to factor XIII deficiency'. As many as 12 cases with haemorrhagic acquired factor XIII deficiency due to its inhibitors were recently found in Japan. Thromb Haemost 2011; 105: 925-7.
10. Souri M, Kaetsu H, Ichinose A. Sushi domains in the B subunit of factor XIII responsible for oligomer assembly. Biochemistry 2008; 47: 8656-64.
11. 2-plasmin inhibitor levels between plasma and serum in patients with severe factor XIII deficiency, including autoimmune hemorrhaphilia due to anti-factor XIII antibodies. Int J Hematol 2012; 95: 47-50.
12. Wada H, Souri M, Matsumoto R, Sugihara T, Ichinose A. Alloantibodies against the B subunit of plasma factor XIII developed in its congenital deficiency. Thromb Haemost 2013; 109: 661-8.
13. Lorand L, Maldonado N, Fradera J, Atencio AC, Robertson B, Urayama T. Haemorrhagic syndrome of autoimmune origin with a specific inhibitor against fibrin stabilizing factor (factor XIII). Br J Haematol 1972; 23: 17-27.
14. Milner GR, Holt PJ, Bottomley J, Maciver JE. Practolol therapy associated with a systemic lupus erythematosus-like syndrome and an inhibitor to factor XIII. J Clin Pathol 1977; 30: 770-3.
15. Lopaciuk S, Bykowska K, McDonagh JM, McDonagh RP, Yount WJ, Fuller CR, Cooperstein L, Gray A Jr, Lorand L. Difference between type I autoimmune inhibitors of fibrin stabilization in two patients with severe hemorrhagic disorder. J Clin Invest 1978; 61: 1196-203.
16. Shinkai K, Nishiwaki H, Takagi A, Ogata K, Yokomaku S. Hemostatic management of severe hemorrhage in a case with factor XIII inhibitor [abstract]. Int J Hematol 1996; 63(Suppl. 1): 291. Japanese.
17. Lorand L, Velasco PT, Rinne JR, Amare M, Miller LK, Zucker ML. Autoimmune antibody (IgG Kansas) against the fibrin stabilizing factor (factor XIII) system. Proc Natl Acad Sci USA 1988; 85: 232-6.
18. Lorand L. Factor XIII: structure, activation, and interactions with fibrinogen and fibrin. Ann N Y Acad Sci 2001; 936: 291-311.
19. Lorand L. Hemorrhagic disorders of fibrin-stabilization. In: Ogston D, Bennett B, eds. Haemostasis: Biochemistry, Physiology, and Pathology. London: Wiley, 1977: 405-23.
20. Lorand L, Losowsky MS, Miloszewski KJ. Human factor XIII: fibrin-stabilizing factor. Prog Hemost Thromb 1980; 5: 245-90.
21. Teruya J, Kinoshita T, Yoshimura Y, Morioka M, Kazama M, Abe T. An inhibitor to factor VIII interacting with its activated catalytic subunit. Rinsho Ketsueki 1986; 27: 1680-7. Japanese.
22. Nakamura S, Kato A, Sakata Y, Aoki N. Bleeding tendency caused by IgG inhibitor to factor XIII, treated successfully by cyclophosphamide. Br J Haematol 1988; 68: 313-19.
23. Fukue H, Anderson K, McPhedran P, Clyne L, McDonagh J. A unique factor XIII inhibitor to a fibrin-binding site on factor XIIIA. Blood 1992; 79: 65-74.
24. Tosetto A, Rodeghiero F, Gatto E, Manotti C, Poli T. An acquired hemorrhagic disorder of fibrin crosslinking due to IgG antibodies to FXIII, successfully treated with FXIII replacement and cyclophosphamide. Am J Hematol 1995; 48: 34-9.
25. Lorand L, Velasco PT, Murthy SN, Lefebvre P, Green D. Autoimmune antibody in a hemorrhagic patient interacts with thrombin-activated factor XIII in a unique manner. Blood 1999; 93: 909-17.
26. Muszbek L, Adány R, Szegedi G, Polgár J, Kávai M. Factor XIII of blood coagulation in human monocytes. Thromb Res 1985; 37: 401-10.
27. Henriksson P, Becker S, Lynch G, McDonagh J. Identification of intracellular factor XIII in human monocytes and macrophages. J Clin Invest 1985; 76: 528-34.
28. Kiesselbach TH, Wagner RH. Demonstration of factor XIII in human megakaryocytes by a fluorescent antibody technique. Ann N Y Acad Sci 1972; 202: 318-28.
29. Adány R, Kiss A, Muszbek L. Factor XIII: a marker of mono- and megakaryocytopoiesis. Br J Haematol 1987; 67: 167-72.
30. Nagy JA, Henriksson P, McDonagh J. Biosynthesis of factor XIII B subunit by human hepatoma cell lines. Blood 1986; 68: 1272-9.
31. Wölpl A, Lattke H, Board PG, Arnold R, Schmeiser T, Kubanek B, Robin-Winn M, Pichelmayr R, Goldmann SF. Coagulation factor XIII A and B subunits in bone marrow and liver transplantation. Transplantation 1987; 43: 151-3.
32. Souri M, Koseki-Kuno S, Takeda N, Degen JL, Ichinose A. Administration of factor XIII B subunit increased plasma factor XIII A subunit levels in factor XIII B subunit knock-out mice. Int J Hematol 2008; 87: 60-8.
33. Daly HM, Carson PJ, Smith JK. Intracerebral haemorrhage due to acquired factor XIII inhibitor - successful response to factor XIII concentrate. Blood Coagul Fibrinolysis 1991; 2: 507-14.
34. Ahmad F, Solymoss S, Poon MC, Berube C, Sullivan AK. Characterization of an acquired IgG inhibitor of coagulation factor XIII in a patient with systemic lupus erythematosus. Br J Haematol 1996; 93: 700-3.
35. Mutch NJ, Koikkalainen JS, Fraser SR, Duthie KM, Griffin M, Mitchell J, Watson HG, Booth NA. Model thrombi formed under flow reveal the role of factor XIII-mediated cross-linking in resistance to fibrinolysis. J Thromb Haemost 2010; 8: 2017-24.
36. 2-antiplasmin cross-linking. Blood 2011; 117: 6371-4.
37. Ajzner E, Schlammadinger A, Kerényi A, Bereczky Z, Katona E, Haramura G, Boda Z, Muszbek L. Severe bleeding complications caused by an autoantibody against the B subunit of plasma factor XIII: a novel form of acquired factor XIII deficiency. Blood 2009; 113: 723-5.
38. Ichinose A. Factor XIII is a key molecule at the intersection of coagulation and fibrinolysis as well as inflammation and infection control. Int J Hematol 2012; 95: 362-70.
39. Krumdieck R, Shaw DR, Huang ST, Poon MC, Rustagi PK. Hemorrhagic disorder due to an isoniazid-associated acquired factor XIII inhibitor in a patient with Waldenström's macroglobulinemia. Am J Med 1991; 90: 639-45.
40. Lorand L, Velasco PT, Hill JM, Hoffmeister KJ, Kaye FJ. Intracranial hemorrhage in systemic lupus erythematosus associated with an autoantibody against factor XIII. Thromb Haemost 2002; 88: 919-23.